Many factors can explain this finding such as lower expression levels of p53 in quiescent CD34+ CML cell populations, or a higher Bcr-Abl kinase activity [14, 43] that may activate alternative survival pathways. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.